Czech National Bank grew its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 3.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 390,897 shares of the medical equipment provider’s stock after acquiring an additional 14,563 shares during the quarter. Czech National Bank’s holdings in Boston Scientific were worth $37,272,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its stake in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. CreativeOne Wealth LLC increased its stake in Boston Scientific by 65.0% in the second quarter. CreativeOne Wealth LLC now owns 12,667 shares of the medical equipment provider’s stock valued at $1,361,000 after purchasing an additional 4,988 shares in the last quarter. RiverFront Investment Group LLC raised its holdings in Boston Scientific by 9.7% in the second quarter. RiverFront Investment Group LLC now owns 5,904 shares of the medical equipment provider’s stock worth $634,000 after purchasing an additional 524 shares during the period. Laurel Wealth Advisors LLC raised its holdings in Boston Scientific by 25,858.3% in the second quarter. Laurel Wealth Advisors LLC now owns 3,115 shares of the medical equipment provider’s stock worth $335,000 after purchasing an additional 3,103 shares during the period. Finally, Advisors Asset Management Inc. boosted its position in shares of Boston Scientific by 17.3% during the second quarter. Advisors Asset Management Inc. now owns 42,032 shares of the medical equipment provider’s stock worth $4,515,000 after purchasing an additional 6,199 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Boston Scientific
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Analyst support: TD Cowen highlighted strong early adoption of BSX’s Agent DCB and kept a Buy rating with a $100 price target, underpinning bullish investor sentiment on multi-year growth potential. Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
- Positive Sentiment: Potential rating upgrade / turnaround view: A Seeking Alpha piece argues BSX is “under pressure but could see a shift in fortunes,” suggesting a rating upgrade could help sentiment if upcoming operational data improves. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
- Positive Sentiment: Bullish “buy the dip” narratives: MarketBeat and other bullish write-ups view the recent pullback as an opportunity tied to pending trial results and long-term device adoption, supporting short-term buying interest. Why Boston Scientific’s Big Dip Could Be a Bigger Opportunity
- Neutral Sentiment: Industry note (unrelated company): Stratus Medical was named to Fortune’s Most Innovative Companies list — a positive for the RFA/chronic pain segment but not directly tied to BSX results. Investors may view it as a sector-level signal rather than company-specific news. Stratus Medical Recognized on Fortune’s America’s Most Innovative Companies List for 2026
- Negative Sentiment: Surge of securities-law firm notices and class-action filings allege misstatements around U.S. electrophysiology volumes; multiple firms (Bronstein, Faruqi, Levi & Korsinsky, Pomerantz, Rosen, Robbins, Bernstein Liebhard, etc.) are soliciting lead-plaintiff candidates and reminders about the May 4, 2026 deadline—heightening litigation risk and headline volatility for BSX. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific Investors of Securities Class Action Deadline on May 4, 2026
- Negative Sentiment: Recent stock weakness and volatility: News outlets and Zacks noted BSX shares have recently traded down more sharply than the broader market, reflecting investor concern over guidance, electrophysiology volumes, and litigation headlines. Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know
Boston Scientific Price Performance
Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently commented on BSX shares. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Barclays reduced their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Wells Fargo & Company lowered their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. dropped their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Stifel Nicolaus cut their price objective on Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, March 20th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $106.27.
Check Out Our Latest Report on Boston Scientific
Insider Transactions at Boston Scientific
In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.50% of the company’s stock.
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Recommended Stories
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
